Rinsho Shinkeigaku (Clinical Neurology)

Symposium 20

Subacute sclerosing panencephalitis (SSPE)

Mitsuaki Hosoya

Department of Pediatrics, Fukushima Medical University

Subacute sclerosing panencephalitis (SSPE) is a progressive and fatal central nervous system disorder that results from a persistent SSPE virus infection. The efficacy of inosine pranobex, an antiviral/immunomodulator agent, remains controversial. Intraventricular interferon-alpha combined with oral inosine pranobex slows the progressive course of SSPE, but does not cure the disease. We examined a wide variety of antiviral compounds for their inhibitory effects on SSPE virus strains in vitro and in vivo, and found that ribavirin had potent inhibitory activity against SSPE. We tried to treat SSPE patients first with high-dose intravenous ribavirin therapy, and then with intraventricular ribavirin therapy. Ribavirin therapy seemed to have a certain effect on clinical courses of patients with SSPE. To reach the conclusion that ribavirin therapy is clinically effective, clinical trials on many cases will be required.
Full Text of this Article in Japanese PDF (230K)

(CLINICA NEUROL, 51: 1047|1050, 2011)
key words: Subacute sclerosing panencephalitis, Ribavirin, intraventricular administration

(Received: 20-May-11)